Clinical Overview & Guidance
Congenital Syphilis Hub
The Pediatric ID Clinical Hub provides essential, evidence-based protocols for the diagnosis, management, and prevention of congenital syphilis. Designed for both healthcare providers and caregivers, this resource ensures clinical excellence in neonatal care.
Diagnosis & Clinical Manifestations
Neonatal Rhinitis ('Snuffles')
One of the earliest clinical signs, appearing as a persistent, often blood-tinged nasal discharge occurring within the first weeks of life.
Dermatological Presentation
A characteristic maculopapular rash, involving the palms and soles, which may progress to desquamation or bullae formation (pemphigus syphilis).
Hepatomegaly & Splenomegaly
Enlargement of the liver and spleen is common, often accompanied by jaundice and laboratory evidence of systemic inflammation or anemia.
Diagnostic Screening Protocols
Diagnosis is confirmed through maternal screen history, physical exam, and specific serological tests including RPR/VDRL titers.
Clinical Management
- Aqueous Crystalline Penicillin G: 50,000 units/kg/dose IV every 12 hours for the first 7 days, then every 8 hours for a total of 10 days.
- Procaine Penicillin G: 50,000 units/kg/dose IM in a single daily dose for 10 days if IV access is unavailable.
- Initial Follow-up: Clinical examination and serologic testing (RPR/VDRL) at 2, 4, 6, and 12 months post-treatment.
- CSF Re-evaluation: Repeat lumbar puncture every 6 months if initial CSF pleocytosis was present until reactive parameters normalize.
- Long-term Monitoring: Ongoing developmental assessments and hearing evaluations up to 2 years of age.
Prevention Strategies
Universal screening for all pregnant women is the most effective way to prevent congenital syphilis. Early detection through routine prenatal testing and prompt treatment of maternal infection can eliminate the risk of transmission to the infant. Public health measures emphasize accessible prenatal care and partner notification to reduce incidence across all communities.
Frequently Asked Questions
What are the primary screening recommendations for pregnant women?
All pregnant women should be screened for syphilis at the first prenatal visit. For those at high risk or in areas with high prevalence, re-screening at 28 weeks and at delivery is strongly advocated to prevent vertical transmission.
How is congenital syphilis diagnosed in a newborn?
Diagnosis involves a combination of maternal history, physical examination of the infant, and quantitative non-treponemal serologic tests (e.g., RPR) performed on the infant's serum, not cord blood. Clinical signs like hepatomegaly or rash also guide the evaluation.
What is the standard treatment regimen for confirmed cases?
Aqueous crystalline penicillin G is the preferred treatment, typically administered intravenously for 10 days. The dosage is adjusted based on the infant's age and weight to ensure optimal therapeutic levels in both the blood and central nervous system.
What long-term follow-up is necessary for exposed infants?
Infants require clinical and quantitative serologic follow-up at 2, 3, 6, and 12 months of age. Serologic tests should decline by 6 months and be non-reactive by 12-18 months. Developmental monitoring is also critical to detect any neurological sequelae.
Can breastfeeding continue during maternal treatment?
Yes, breastfeeding is generally encouraged. Syphilis is not transmitted through breast milk unless an active syphilitic lesion is present on the breast. Mothers should consult with their healthcare provider to ensure safety and proper hygiene during the treatment course.